What is Kymera Therapeutics's common stock?

Kymera Therapeutics (KYMR) reported common stock of $8K in Q1 2026.

How has Kymera Therapeutics's common stock changed year-over-year?

Kymera Therapeutics's common stock increased by 14.3% year-over-year, from $7K to $8K.

What is the long-term trend for Kymera Therapeutics's common stock?

Over 5 years (2020 to 2025), Kymera Therapeutics's common stock has grown at a 14.9% compound annual growth rate (CAGR), from $4K to $8K.

What does common stock mean?

The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Kymera Therapeutics KYMR Common Stock

Common Stock at other companies

ImmunityBio, Inc.IBRX

1.7B+22.2%

Krystal Biotech, Inc.KRYS

80M0.0%

Spyre Therapeutics, Inc.SYRE

400M0.0%

IncyteINCY

400M0.0%

Protagonist TherapeuticsPTGX

——

Immunovant, Inc.IMVT

——

Other financials

Income statement

See full

Revenue$34.4M+55.5%

Operating income-$84.2M-13.1%

Net income-$69.2M-5.6%

EPS (diluted)-$0.71+13.4%

Balance sheet

See full

Cash & equivalents$144.1M+60.2%

Total debt$82.2M-6.5%

Total equity$1.5B+95.8%

Total assets$1.7B+81.7%

Cash flow

See full

Operating cash flow-$88.8M-12.2%

CapEx$434.0K-7.1%

Free cash flow-$89.3M-12.1%

Valuation

See full

Market cap$7.44B+283%

Enterprise value$7.38B+280%

P/S144.5×+111×

Profitability

See full

Operating margin-697.7%+635pp

Net margin-612%+602pp

FCF margin-474%+92.4pp

Returns & leverage

See full

Return on equity-27.1%-3.7pp

Debt / equity0.1×-0.1×

Current ratio10.8×+2.3×

Where this comes from

Reported directly by Kymera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kymera Therapeutics's common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Kymera Therapeutics's common stock?: Kymera Therapeutics (KYMR) reported common stock of $8K in Q1 2026.
How has Kymera Therapeutics's common stock changed year-over-year?: Kymera Therapeutics's common stock increased by 14.3% year-over-year, from $7K to $8K.
What is the long-term trend for Kymera Therapeutics's common stock?: Over 5 years (2020 to 2025), Kymera Therapeutics's common stock has grown at a 14.9% compound annual growth rate (CAGR), from $4K to $8K.
What does common stock mean?: The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).